L. Jonsson

发表

An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003

B. Winblad, A. Wimo, L. Jönsson, 2006, Dementia and Geriatric Cognitive Disorders.

Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?

Niklas Zethraeus, Bengt Jonsson, Magnus Johannesson, 2009 .

Health economic evaluation of treatments for Alzheimer′s disease: impact of new diagnostic criteria

S. Gauthier, C. Brayne, A. Wimo, 2014, Journal of internal medicine.

SCOPE: a scorecard for osteoporosis in Europe

R. Rizzoli, J. Kanis, W. Lems, 2013, Archives of Osteoporosis.

Differences in resource use and costs of dementia care between European countries: Baseline data from the ictus study

T. Rapp, Anders Gustavsson, B. Winblad, 2010, The journal of nutrition, health & aging.

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

N. Maniadakis, G. Kourlaba, L. Jonsson, 2013, BMC Health Services Research.

Assessment of potential measures in models of progression in Alzheimer disease

J. Darbà, M. Buxton, T. Mittendorf, 2010, Neurology.

The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia

A. Zbrozek, A. Wimo, L. Jonsson, 2010, The journal of nutrition, health & aging.

Potential cost-effectiveness of individualized medicine in prodromal Alzheimer's disease by demographic, clinical and cerebrospinal fluid proteomics factors

P. Visser, R. Handels, L. Jonsson, 2023, medRxiv.